Lexeo TherapeuticsLXEO
About: Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Employees: 72
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
173% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 11
30% more funds holding
Funds holding: 69 [Q3] → 90 (+21) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
0.68% less ownership
Funds ownership: 89.94% [Q3] → 89.26% (-0.68%) [Q4]
28% less capital invested
Capital invested by funds: $269M [Q3] → $194M (-$74.6M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Mitchell Kapoor 30% 1-year accuracy 56 / 186 met price target | 617%upside $23 | Buy Reiterated | 8 Apr 2025 |
Chardan Capital Geulah Livshits 5% 1-year accuracy 3 / 59 met price target | 585%upside $22 | Buy Maintained | 8 Apr 2025 |
RBC Capital Luca Issi 6% 1-year accuracy 3 / 54 met price target | 523%upside $20 | Outperform Maintained | 25 Mar 2025 |
Leerink Partners Mani Foroohar 20% 1-year accuracy 3 / 15 met price target | 461%upside $18 | Outperform Maintained | 24 Mar 2025 |
Financial journalist opinion
Based on 4 articles about LXEO published over the past 30 days









